Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization
10-May-2010 -
Bayer Schering Pharma AG announced that it has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA). A Phase III clinical program for ...
atrophy
Bayer
Bayer Schering
+4